Hepatolithiasis associated with cholangiocarcinoma
- PMID: 7676713
- DOI: 10.1007/BF00294744
Hepatolithiasis associated with cholangiocarcinoma
Abstract
Hepatolithiasis is a risk factor for cholangiocarcinoma. It is difficult to make an accurate diagnosis before treatment. In a retrospective study, we identified characteristic clinical features of 103 patients with hepatolithiasis (group H) and 10 patients with hepatolithiasis associated with cholangiocarcinoma (group HC), and examined the methods for diagnosis and treatment. The main symptoms were abdominal pain, fever, and jaundice, although few patients in group HC had jaundice. The incidence of abnormal serum levels of carcinoembryonic antigen (CEA) in group HC was higher than in group H. The incidence of cholangiocarcinoma in cases in which most of the stones were present in the intrahepatic ducts of the left lobe (type I-L) was higher than the incidence in the other patients. Of the patients who underwent portography in group HC, portal veins in the portion of the liver containing the cholangiocarcinoma were not seen, and this region was atrophic in the operative specimens. The incidence of portal obstruction in portograms in group HC was higher than that in group H. The possibility of carcinoma should be kept in mind if there are high levels of CEA, if the location of the stones is classified as type I-L, or if portal veins cannot be seen on portograms. In such patients, liver resection should be considered because there may be undiagnosed cholangiocarcinoma.
Similar articles
-
Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.Hepatogastroenterology. 2003 Jan-Feb;50(49):8-12. Hepatogastroenterology. 2003. PMID: 12629979
-
Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries.Eur J Gastroenterol Hepatol. 2002 Sep;14(9):1025-7. doi: 10.1097/00042737-200209000-00016. Eur J Gastroenterol Hepatol. 2002. PMID: 12352225
-
Cholangiocarcinoma Risk as Long-term Outcome After Hepatic Resection in the Hepatolithiasis Patients.World J Surg. 2015 Jun;39(6):1537-42. doi: 10.1007/s00268-015-2965-0. World J Surg. 2015. PMID: 25648078
-
Clinical presentation, risk factors and staging systems of cholangiocarcinoma.Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):245-52. doi: 10.1016/j.bpg.2015.02.001. Epub 2015 Feb 14. Best Pract Res Clin Gastroenterol. 2015. PMID: 25966425 Review.
-
[Cholangiocarcinoma--bile ducts cancer].Wiad Lek. 2003;56(1-2):57-60. Wiad Lek. 2003. PMID: 12901270 Review. Polish.
Cited by
-
Surgical management of proximal bile duct cancers.Langenbecks Arch Surg. 2012 Aug;397(6):869-79. doi: 10.1007/s00423-012-0928-6. Epub 2012 Mar 6. Langenbecks Arch Surg. 2012. PMID: 22391776 Review.
-
Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea.J Korean Med Sci. 2010 Jul;25(7):1011-6. doi: 10.3346/jkms.2010.25.7.1011. Epub 2010 Jun 17. J Korean Med Sci. 2010. PMID: 20592891 Free PMC article.
-
Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma.World J Gastrointest Endosc. 2010 Nov 16;2(11):357-61. doi: 10.4253/wjge.v2.i11.357. World J Gastrointest Endosc. 2010. PMID: 21173912 Free PMC article.
-
Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.World J Surg. 2004 Oct;28(10):995-1000. doi: 10.1007/s00268-004-7447-8. Epub 2004 Sep 29. World J Surg. 2004. PMID: 15573254
-
Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment.J Gastrointest Surg. 2011 Apr;15(4):608-13. doi: 10.1007/s11605-011-1419-8. Epub 2011 Jan 19. J Gastrointest Surg. 2011. PMID: 21246412
References
MeSH terms
Substances
LinkOut - more resources
Medical